COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

202409_EB_Metabolic Probiotic_823x4622 (1).png

You’re likely familiar with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA) used in commercially available prescription medicines for treatment of type 2 diabetes and obesity. Are you aware that GLP-1 — the hormone semaglutide is designed to induce — is naturally produced by the body to help promote healthy blood sugar levels, curb cravings and maintain a healthy weight? Or aware of the bacterium in the gut microbiota that induces natural production of GLP-1?

20240812_BB-Pediatric Dosing_823x462.jpg

Developing pharmaceutical products for pediatric patients typically involves creating age-appropriate, weight-based dosing or considering complex formulations. Many commercially available drugs are not tailored for children, often containing unsafe excipients or being provided in dosage forms unsuitable for pediatric use.

BB_Designated Person_800w.jpg

Revisions to USP 795, which went into effect November 1, 2023, introduce a new position for compounders: the Designated Person. This person or group of persons are responsible for creating and overseeing training, reviewing compounding staff competencies and maintaining training records for all compounding staff members. In this blog, we review the key responsibilities of the Designated Person for training standards and explore solutions that may help drive greater efficiencies in your compounding pharmacy’s training program.

BB_Tall Man Lettering_800w.jpg

Many regulatory and nonprofit agencies, including the FDA and the Institute for Safe Medication Practices (ISMP), recommend use of tall man lettering on drug labels. Learn why PCCA is adopting the technique for our active pharmaceutical ingredient (API) labels.

202406_BB_Acne_900w.jpg

Although acne commonly occurs in adolescents and some adults, it can leave lasting effects, including scarring. With June designated as Acne Awareness Month, gain clinical understanding of causes and potential treatments that may help your patients.

PIPM-BB_823x462.png

Zachary Green, CPhT, Director of Professional Affairs at the Pharmacy Technician Certification Board (PTCB) and Director of the Pharmacy Technician Educators Council (PTEC), shares his experience and insights on pharmacy technician certification, career opportunities and more.

202405_BB_Questions Freelancers.jpg

Marketing your compounding pharmacy in the digital space is no longer an option — it’s a necessity. Skilled freelancers can help you get started or expand your digital footprint by providing compelling written content, engaging designs or strategic social media management. But how do you know you’re hiring the right professionals for the job? Ask these essential questions during the interview process.

202405_BB_Quinacrine_900w.jpg

As one of the most studied synthetic drugs in modern history, quinacrine HCI was first used as an antimalarial and later to treat rheumatic skin diseases, including lupus. With May designated as Lupus Awareness month, learn more about quinacrine HCI and the twists and turns of its storied past.

202404_BB_ACT- Patients_900w.jpg

Compounding pharmacists are committed to helping their patients live healthier, better lives —and key to this is ensuring their patients have continuing access to lawfully prescribed, personalized medications tailored to their individual needs.

202402_BB_EoE_823x462.jpg

In February, the FDA approved the first and only oral treatment for eosinophilic esophagitis (EoE) that contains the active pharmaceutical ingredient (API) budesonide at a strength of 2 mg/10mL, which may sound familiar to many compounders.1 How does this affect compounders and what other potential options are available to patients?